One Mushroom Trip Helped More Smokers Quit Than Months of Nicotine Patches
A groundbreaking pilot study has dealt a striking blow to conventional smoking cessation methods and psychedelics are at the center of it.
Researchers at Johns Hopkins University School of Medicine have found that a single high-dose psilocybin session, when paired with cognitive behavioral therapy (CBT), helped over 40% of smokers stay cigarette-free for six months. By comparison, only 1 in 10 participants using nicotine patches achieved the same milestone.
The findings, published in JAMA Network Open, are being called a signal that psilocybin “should move forward in the FDA process toward potential approval” for smoking cessation.
What the Trial Found
The study enrolled 82 psychiatrically healthy adult smokers between January 2015 and May 2023 at Johns Hopkins Bayview Medical Center. Participants averaged nearly 16 cigarettes a day and had tried to quit a median of six times before. All received 13 weeks of CBT. At week five, they were randomly assigned to either a single oral dose of psilocybin (30 mg/70 kg) or a standard nicotine patch regimen.
The gap in outcomes was stark:
6-month abstinence: 40.5% (psilocybin) vs. 10% (nicotine patch)
7-day abstinence before the 6-month visit: 52.4% vs. 25%
Daily cigarette reduction through month 6: Psilocybin users smoked roughly half as much on average
No serious adverse events were reported. Temporary spikes in blood pressure and mild nausea were the most common side effects expected with psilocybin and were managed within the supervised session. One participant required sublingual nitroglycerin for a blood pressure spike, but recovered without complication.
How Psilocybin May Work on Addiction
Lead researcher Matthew W. Johnson, PhD, describes psilocybin as a biological facilitator of psychotherapeutic change rather than simply a chemical intervention.
“The mind is put in a temporary state with increased flexibility,” Johnson explained. “People have insights and changes in the way they view themselves and their problems and these psychological effects often last well beyond the acute drug experience.”
This shift in mental perspective sometimes called “the trip” appears to be the active ingredient for therapeutic benefit. Johnson suggests that what psychedelics share across disorders is a transdiagnostic mechanism: a broad-spectrum loosening of rigid thought patterns that underlies depression, anxiety, and addiction alike.
What makes the smoking result particularly interesting is the nature of tobacco dependence itself. Unlike opioids or alcohol, nicotine rarely destroys lives in the short term it just kills people slowly. The fact that psilocybin works here, Johnson argues, suggests it targets something fundamental to addiction itself, not just the acute reward circuits that most cessation drugs address.
Inside the Dosing Session
The psilocybin experience was carefully structured. Participants received psychoeducation beforehand, then spent the session lying on a couch, wearing eye shades, listening to a curated music program through headphones. They were encouraged to direct their attention inward.
The next day, 90.5% of psilocybin participants reported full abstinence — compared to 80% of nicotine patch users. That early lead held and widened significantly over the following months.
The Bigger Picture
Johnson is careful to note the limitations. The trial was unblinded, lacked racial diversity (89% of participants were white), and drew heavily from participants with prior psychedelic experience nearly 65%, compared to a national average of around 14%. That recruitment skew may mean results look better than they’d be in a general population.
Psilocybin also remains a Schedule I substance in the U.S., meaning it is not currently available as a clinical treatment. Johnson advises clinicians to watch this space, while making clear to curious patients that the safety outcomes seen in the study depend heavily on the controlled, supervised environment in which they occurred.
Still, the promise is hard to ignore. Prior research has shown psilocybin’s potential in treating depression, alcohol use disorder, and cancer-related distress. Smoking cessation now joins that list and given that tobacco claims more lives than all other addictive substances combined, the stakes couldn’t be higher.
Psilocybin therapy requires only a handful of supervised sessions, which sharply limits the window for adverse events. Standard smoking cessation medications, taken daily for weeks, carry more sustained risk and far greater adherence challenges a practical consideration that may factor into future regulatory conversations.
